Research Journal for Veterinary Practitioners

Research Article
Res. j. vet. pract. 3 (3): 58 - 68
http://dx.doi.org/10.14737/journal.rjvp/2015/3.3.58.68
View Full HTML
Download PDF

James D. Archer

Applied Research Laboratory, Veterinary Studies Project, 25104 Broadwell Avenue, Harbor City, California 90710, USA.

*Correspondence | James D Archer, Applied Research Laboratory, Veterinary Studies Project, 25104 Broadwell Avenue, Harbor City, California 90710, USA; Email: photoresearch@sbcglobal.net

Abstract
The objectives of this study were to examine whether AB070597, a dietary supplement of amino acids and a peptide, had an effect on progressive increases in blood-serum creatinine concentration (SCr) and disease advancement in cats with chronic kidney disease (CKD). Fifty-nine privately owned cats with confirmed CKD were enrolled in this study. Twenty-seven cats were given AB070597 orally twice daily, and 32 remaining cats served as non-treated controls. Cats participated in the study for 24-104 weeks. Cats received standard care, including subcutaneous fluids, antibiotics, and anti-hypertensive therapy, as directed by their veterinarians, with the exception that dietary protein was not restricted. Blood-serum creatinine concentrations were measured at the beginning of the trial and at 12-week intervals. Body weight was measured at study beginning and at varying times during the study. The stage of the renal disease at the onset of the trial was scored using the criteria set out by the International Renal Interest Society (IRIS). Bi-daily oral administration of AB070597 significantly reduced median SCr for the overall study period (P=0.0084) and at all-time points (P≤0.0269), except week 84 (P=0.0747). Mean disease stage was reduced in the treatment group when compared to the control group (P=0.0184) at the end of the study. Treated cats were 19.8 times more likely to have a lower disease stage at the end of the study compared to untreated cats. Body weight increased in 59%, was unchanged in 15%, and decreased in 26% of treated cats whereas body weight increased in 6%, was unchanged in 10%, and decreased in 84% of untreated cats. Together, these findings suggest that AB070597 may be a useful tool for stabilizing SCr in some cats with CKD and that the formulation warrants further study.

Keywords | AB070597, cats, chronic kidney disease, dietary supplement, renal insufficiency

Editor | Muhammad Abubakar, National Veterinary Laboratories, Islamabad, Pakistan.

Received | June 12, 2015; Revised | July 23, 2015; Accepted | July 25, 2015; Published | August 03, 2015

Citation | Archer JD (2015). Effect of AB070597 on blood-serum creatinine concentration in cats with chronic kidney disease. Res. J. Vet. Pract. 3(3): 58-68.

ISSN | 2308-2798

Copyright © 2015 Archer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.